The transmission and toxicity of polymer-bound doxorubicin-containing exosomes derived from human adenocarcinoma cells
Abstract
Background: Exosomes are extracellular vesicles with the ability to encapsulate bioactive molecules, such as therapeutics. This study identified a new exosome mediated route of doxorubicin and poly(N-(2-hydroxypropyl)methacrylamide) (pHPMA)-bound doxorubicin trafficking in the tumor mass. Materials & methods: Exosome loading was achieved via incubation of the therapeutics with an adherent human breast adenocarcinoma cell line and its derived spheroids. Exosomes were characterized using HPLC, nanoparticle tracking analysis (NTA) and western blotting. Results: The therapeutics were successfully loaded into exosomes. Spheroids secreted significantly more exosomes than adherent cells and showed decreased viability after treatment with therapeutic-loaded exosomes, which confirmed successful transmission. Conclusion: To the best of our knowledge, this study provides the first evidence of pHPMA-drug conjugate secretion by extracellular vesicles.
Graphical abstract
Cancerostatics delivered to the tumor site via the bloodstream facilitated by the enhanced permeability and retention effect are taken up by peripheral tumor cells. Inside the multivesicular bodies cancerostatics (free, polymer-bound or cleaved from polymer backbone) are loaded into exosomes, secreted into the extracellular space and taken up by cells deeper inside the tumor mass. Cancerostatics maintain toxicity throughout the process.
Plain language summary
Background: In cancer treatment, low-molecular-weight drugs (e.g., doxorubicin [DOX]) with a broad spectrum of side effects are commonly used. Through their conjugation with hydrophilic polymers – N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers – for example, most of the side effects can be reduced. These drug–polymer conjugates are delivered via bloodstream into the tumor. This study aimed to identify a new exosome-mediated route of DOX and polyHPMA(pHPMA)–DOX conjugates trafficking inside the tumor mass. Exosomes are small lipid membrane vesicles constitutively released from most of the cell types, including the tumor cells. Exosomes are able to encapsulate low-molecular-weight drugs. Methods: Exosomes were loaded with DOX and pHPMA-DOX in vitro via coincubation with cancer cells. Exosomes were isolated from the conditioned-cultivation medium after their release from cells and characterized (size, numbers, protein marker profiles). Results: The therapeutics were successfully loaded into exosomes and transmitted to the tumor cells. To the best of our knowledge, this is the first evidence of the pHPMA–drug conjugate secretion by exosomes.
Papers of special note have been highlighted as: • of interest
References
- 1. . Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells 8(7), 727 (2019). • An extensive review providing information on the family of extracellular vesicles.
- 2. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4(1), 27066 (2015).
- 3. . Molecular mechanism of multivesicular body biogenesis by ESCRT complexes. Nature. 464(7290), 864–869 (2010).
- 4. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 14(7), 677–685 (2012).
- 5. . Pathways and mechanisms of endocytic recycling. Nat. Rev. Mol. Cell Biol. 10(9), 597–608 (2009).
- 6. Signaling pathways in exosomes biogenesis, secretion and fate. Genes (Basel). 4(2), 152–170 (2013).
- 7. Cancer exosomes in cerebrospinal fluid. Transl. Cancer Res. 6(Suppl. 8), (2017).
- 8. . Body fluid derived exosomes as a novel template for clinical diagnostics. J. Transl. Med. 9, 86 (2011).
- 9. Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study. J. Extracell. Vesicles 6(1), (2017).
- 10. Molecular characterization of exosome-like vesicles from breast cancer cells. BMC Cancer 14, 44 (2014).
- 11. Molecular characterization of dendritic cell-derived exosomes. J. Cell Biol. 147(3), 599–610 (1999).
- 12. Identification of RNA-binding proteins in exosomes capable of interacting with different types of RNA: RBP-facilitated transport of RNAs into exosomes. PLOS ONE. 13(4), e0195969–e0195969 (2018).
- 13. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183(3), 1161–1172 (1996).
- 14. . Tissue-factor–bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 106(5), 1604–1611 (2005).
- 15. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood. 104(10), 3257–3266 (2004).
- 16. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J. Extracell. Vesicles 6(1), 1324730 (2017).
- 17. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341 (2011).
- 18. Interaction of spin-labeled HPMA-based nanoparticles with human blood plasma proteins – the introduction of protein-corona-free polymer nanomedicine. Nanoscale 10(13), 6194–6204 (2018).
- 19. . Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res. 21(11), 1341–1358 (1987).
- 20. Improved tumor-specific drug accumulation by polymer therapeutics with pH-sensitive drug release overcomes chemotherapy resistance. Mol. Cancer Ther. 15(5), 998–1007 (2016). • The demonstration of polymer-bound therapeutics superiority over free low-molecular weight drug.
- 21. . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 46(12 Part 1), 6387–6392 (1986).
- 22. . Intracellular trafficking and subcellular distribution of a large array of HPMA copolymers. Biomacromolecules. 10(7), 1704–1714 (2009).
- 23. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J. Control. Release. 87(1–3), 89–105 (2003).
- 24. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J. Cell. Physiol. 204(2), 522–531 (2005).
- 25. The effect of primary cancer cell culture models on the results of drug chemosensitivity assays: the application of perfusion microbioreactor system as cell culture vessel. Biomed Res. Int. 2015, 470283 (2015).
- 26. N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation. Eur. J. Pharm. Sci. 41(3–4), 473–482 (2010).
- 27. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J. Drug Target. 12(8), 477–489 (2004).
- 28. . Stereogradient polymers formed by controlled/living radical polymerization of bulky methacrylate monomers. Angew. Chem. Int. Ed. Engl. 48(11), 1991–1994 (2009).
- 29. N-(2-hydroxypropyl)methacrylamide-based linear, diblock, and starlike polymer drug carriers: advanced process for their simple production. Biomacromolecules. 19(10), 4003–4013 (2018).
- 30. Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. effect of spacer on drug release and in vitro cytotoxicity. Macromol. Biosci. 2(1), 43–52 (2002).
- 31. The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization. Physiol. Res. 64(Suppl. 1), S41–9 (2015).
- 32. Polymer cancerostatics targeted by recombinant antibody fragments to GD2-positive tumor cells. Biomacromolecules. 20(1), 412–421 (2019).
- 33. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet. Genomics 21(7), 440–446 (2011).
- 34. . Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 97(11), 2869–2879 (2003).
- 35. . 3D cell culture stimulates the secretion of in vivo like extracellular vesicles. Sci. Rep. 9(1), 1–14 (2019).
- 36. Three-dimensional spheroid culture increases exosome secretion from mesenchymal stem cells. Tissue Eng. Regen. Med. 15(4), 427–436 (2018). • The comparison of secretion dynamics of 2D and 3D mesenchymal stem cell cultures.
- 37. 3D cellular architecture affects microRNA and protein cargo of extracellular vesicles. Adv. Sci. 6(4), (2019).
- 38. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates. J. Drug Target. 22(7), 648–657 (2014).
- 39. Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60. Mol. Pharm. 6(2), 396–406 (2009).
- 40. . Monitoring doxorubicin cellular uptake and trafficking using in vitro Raman microspectroscopy: short and long time exposure effects on lung cancer cell lines. Anal. Bioanal. Chem. 409(5), 1333–1346 (2017).
- 41. . Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br. J. Cancer. 94(6), 863–869 (2006).
- 42. Therapeutic use of curcumin-encapsulated and curcumin-primed exosomes. J. Cell. Physiol. 234(6), 8182–8191 (2019).
- 43. Endocytotic uptake of hpma-based polymers by different cancer cells: Impact of extracellular acidosis and hypoxia. Int. J. Nanomed. 12, 5571–5584 (2017). • Describes the variety of factors that can affect polymer uptake in cancer cells.
- 44. Cellular uptake and intracellular trafficking of Poly(N-(2-hydroxypropyl) methacrylamide). Biomacromolecules. 20(1), 231–242 (2019).
- 45. Drug-loaded exosomal preparations from different cell types exhibit distinctive loading capability, yield, and antitumor efficacies: a comparative analysis. Int. J. Nanomed. 14, 531–541 (2019). • Demonstrates donor-cell-specific differences in exosomes and drug-loading abilities.
- 46. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J. Control. Release. 192, 262–270 (2014).
- 47. . Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J. Biol. Chem. 280(24), 23349–23355 (2005).
- 48. . Tetraspanins in extracellular vesicle formation and function. Front. Immunol. 5(SEP), 1–12 (2014).
- 49. Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. PLOS ONE 13(2), e0191109.
- 50. . Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle. Onco. Targets. Ther. 11, 5753–5762 (2018).
- 51. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells. J. Control. Release 220, 727–737 (2015).
- 52. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat. Commun. 3 (2012).
- 53. Polymeric anticancer drugs with pH-controlled activation. Int. J. Pharm. 277(1–2), 63–72 (2004).
- 54. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl) methacrylamide copolymers through an amide or hydrazone bond. Mol. Pharm. 7(4), 1027–1040 (2010).
- 55. . HPMA copolymer-based nanomedicines in controlled drug delivery. J. Pers. Med. 11(2), (2021).
- 56. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. Theranostics 10(8), 3474–3487 (2020).
- 57. . Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 12, 421 (2012).
- 58. Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells. Mol. Ther. Nucl. Acids 27, 611–620 (2022).
- 59. . Membrane-decorated exosomes for combination drug delivery and improved glioma therapy. Langmuir 38(1), 299–308 (2022).
- 60. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale 12(19), 10854–10862 (2020).
- 61. Personalized medicine: recent progress in cancer therapy. Cancers 12(4), (2020).